Latest Eikon Therapeutics News & Updates

See the latest news and media coverage for Eikon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eikon Therapeutics (Eikon)

Late-stage clinical biopharmaceutical company

Latest news about Eikon Therapeutics (Eikon)

April 22 Eikon

Eikon presents oncology pipeline data at ASCO

Six abstracts cover EIK1001 in lung cancer and melanoma, EIK1003 PARP1 inhibitor, and EIK1005 WRN inhibitor studies.
April 18 Eikon

Eikon presents oncology pipeline updates at AACR 2026

Updates cover EIK1001 in melanoma, EIK1004 PARP1 inhibitor, and EIK1005 WRN inhibitor. Presentations occur in poster sessions on April 19 and 21.
March 30 Eikon

Eikon Therapeutics announces Q4 and full year 2025 financial results

Closed $381M IPO, completed Phase 2 enrollment for EIK1001, provides pipeline updates. Cash funds operations into 2H 2027.
February 6 Eikon

Eikon Therapeutics announces pricing of upsized IPO

The company priced 21,177,600 shares at $18.00 each, expecting $381 million in gross proceeds. Trading begins February 5, 2026 on Nasdaq under 'EIKN'.

March 30 Markets Insider

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2...
March 30 Quiver Quantitative

Eikon Therapeutics Completes Upsized IPO Raising $381 Million and Advances Key Clinical Trials in Oncology | Quiver Quantitative

General and administrative expenses ... mismanagement or inefficiencies. Total stockholders’ deficit of $879.0 million as of December 31, 2025, reflecting serious concern about the company's...
March 27 Seeking Alpha

EIKN Eikon Therapeutics, Inc.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below...
March 20 The Globe and Mail

Eikon Therapeutics completes IPO and updates governance documents

Eikon Therapeutics, Inc. ( (EIKN)) just unveiled an update. On February 6, 2026, Eikon Therapeutics, Inc. completed its initial public offering of common stock and...

Never miss news about Eikon

Track Eikon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Discover what's making headlines across other trending companies.